(Total Views: 533)
Posted On: 05/08/2020 2:45:11 PM
Post# of 153907
Manuscript Describes How CytoDyn’s Leronlimab Disrupts CCL5/RANTES-CCR5 Pathway
Manuscript Posted Online to Research Square and MedRxiv Pre-print Server
VANCOUVER, Washington, May 05, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced a pre-print version of the manuscript has been made publicly available on posting with Research Square and MedRxiv describing the immunological mechanism by which leronlimab restores immune function and impacts disease in COVID-19 patients. Consistent with CytoDyn’s commitment to disseminate results to inform the public health response to SARS-CoV-2, the manuscript has been made publicly available.
The manuscript is entitled: Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19
The pre-print full manuscript can be accessed at:
www.researchsquare.com/article/rs-26517/v1
www.medrxiv.org/content/10.1101/2020.05.02.20084673v1
Manuscript Posted Online to Research Square and MedRxiv Pre-print Server
VANCOUVER, Washington, May 05, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced a pre-print version of the manuscript has been made publicly available on posting with Research Square and MedRxiv describing the immunological mechanism by which leronlimab restores immune function and impacts disease in COVID-19 patients. Consistent with CytoDyn’s commitment to disseminate results to inform the public health response to SARS-CoV-2, the manuscript has been made publicly available. The manuscript is entitled: Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19
The pre-print full manuscript can be accessed at:
www.researchsquare.com/article/rs-26517/v1
www.medrxiv.org/content/10.1101/2020.05.02.20084673v1
(0)
(0)
